Kriya Therapeutics

Focus: Kriya Therapeutics is a Series C+ gene therapy biotech focused on ophthalmology and inflammatory diseases, headquartered in Redwood City, CA.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES C +

Total Funding

$900M

Open Jobs

About Kriya Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Kriya Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

VV-14295

Geographic Atrophy Secondary to Age-related Macular Degeneration

PHASE_1_2

Clinical Trials (1)

NCT06765980A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Phase 1/2

Help build intelligence for Kriya Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage gene therapy platform with two Phase 1/2 programs addressing high-unmet-need indications (thyroid eye disease and geographic atrophy)
Series C+ funding stage typically offers meaningful equity upside and operational autonomy before institutional pressures of later rounds
Redwood City location provides access to Silicon Valley biotech ecosystem and talent pool

Watch Out For

Zero current job openings and no public hiring data suggests company may be in a consolidation or pivot phase post-Series C
No marketed products, zero revenue, and early clinical stage (Phase 1/2 only) means minimal near-term catalysts and extended timeline to value creation
Sparse public information (no employee count, funding amounts, recent news) raises transparency concerns about company trajectory

Generated by Claude from Kriya Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

VV-14305

Thyroid Eye Disease (TED)

PHASE_1_2

Clinical Trials (1)

NCT07404111A Study of VV-14305 for the Treatment of Thyroid Eye Disease

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Endocrinology, Ophthalmology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Endocrinology

1 pipeline

Ophthalmology

1 pipeline

Marketed

Pipeline

Visa Sponsorship

H-1B Petitions (FY2023)

Approved

Denied

Rate

Source: USCIS H-1B Employer Data Hub

Private Funding (SEC Form D)

Sep 2025 (amended)

Aug 2025

Jul 2023 (amended)

May 2022